Association of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 with the risk of ovarian cancer: A systematic review and meta-analysis

Wang,Qiao; Bian,Ce; Peng,Hongling; He,Lei; Zhao,Xia

doi:10.3892/mco.2015.516

Association of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 with the risk of ovarian cancer: A systematic review and meta-analysis

Authors:
- Qiao Wang
- Ce Bian
- Hongling Peng
- Lei He
- Xia Zhao
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: February 25, 2015 https://doi.org/10.3892/mco.2015.516
Pages: 623-628

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin‑like growth factor 1 (IGF‑1) and its main binding protein (IGFBP‑3) in blood have been associated with the risk of several types of cancer. However, epidemiological studies have inconsistent results regarding the association of circulating IGF‑1/IGFBP‑3 levels with ovarian cancer risk. A systematic review of the prospective studies was conducted using meta‑analysis to evaluate the existing evidence. Pubmed and Embase databases were searched to identify the relevant studies published before May 1, 2014. Four highly qualified studies with a total of 627 cases and 1,358 controls were finally included in the meta‑analysis. Random effects meta‑analysis was conducted by combining study‑specific odds ratios (ORs) of ovarian cancer for the highest verses lowest exposure levels. A dose‑response association was further assessed by relating the log of ORs for different exposure levels. As a result, the pooled ORs for the highest verses lowest categories of IGF‑1/IGFBP‑3 were 0.85 [95% confidence interval (CI), 0.51‑1.40]/0.78 (95% CI, 0.43‑1.40). In the subgroup analyses, the pooled ORs of IGF‑1/IGFBP‑3 were 1.89 (95% CI, 0.64‑5.59)/1.08 (95% CI, 0.50‑2.32) for the subgroup with cases diagnosed at <55 years, and 0.74 (95% CI, 0.50‑1.08)/0.98 (95% CI, 0.73‑1.33) for the subgroup with cases diagnosed at ≥55 years. No linear association between circulating IGF‑1/IGFBP‑3 levels and ovarian cancer risk was identified. As no significant association of IGF‑1/IGFBP‑3 with ovarian cancer risk was identified in the present meta‑analysis of existing studies, more studies with greater quality are required in the future.

View Figures

View References

1	King ER and Wong KK: Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Patents Anticancer Drug Discov. 7:14–30. 2012. View Article : Google Scholar
2	Adams TE, Epa VC, Garrett TP and Ward CW: Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 57:1050–1093. 2000. View Article : Google Scholar : PubMed/NCBI
3	Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 16:3–34. 1995. View Article : Google Scholar : PubMed/NCBI
4	Khandwala HM, McCutcheon IE, Flyvbjerg A and Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 21:215–244. 2000. View Article : Google Scholar : PubMed/NCBI
5	Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM and Egger M: Insulin-like growth factor (IGF)-I, IGF binding protein-3 and cancer risk: systematic review, and meta-regression analysis. Lancet. 363:1346–1353. 2004. View Article : Google Scholar : PubMed/NCBI
6	Toniolo P, Bruning PF, Akhmedkhanov A, et al: Serum insulin-like growth factor-I and breast cancer. Int J Cancer. 88:828–832. 2000. View Article : Google Scholar : PubMed/NCBI
7	Stattin P, Bylund A, Rinaldi S, et al: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 92:1910–1917. 2000. View Article : Google Scholar : PubMed/NCBI
8	Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 279:563–566. 1998. View Article : Google Scholar : PubMed/NCBI
9	Palmqvist R, Hallmans G, Rinaldi S, et al: Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 50:642–646. 2002. View Article : Google Scholar : PubMed/NCBI
10	Peeters PH, Lukanova A, Allen N, et al: Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 14:81–90. 2007. View Article : Google Scholar : PubMed/NCBI
11	Lukanova A, Lundin E, Toniolo P, et al: Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer. 101:549–554. 2002. View Article : Google Scholar : PubMed/NCBI
12	Tworoger SS, Lee IM, Buring JE, Pollak MN and Hankinson SE: Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev. 16:1691–1695. 2007. View Article : Google Scholar : PubMed/NCBI
13	Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 283:2008–2012. 2000. View Article : Google Scholar : PubMed/NCBI
14	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
15	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
16	Greenland S and Longnecker MP: Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 135:1301–1309. 1992.PubMed/NCBI
17	Thompson SG and Sharp SJ: Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 18:2693–2708. 1999. View Article : Google Scholar : PubMed/NCBI
18	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
19	Dal Maso L, Augustin LS, Franceschi S, et al: Association between components of the insulin-like growth factor system and epithelial ovarian cancer risk. Oncology. 67:225–230. 2004. View Article : Google Scholar : PubMed/NCBI
20	Fox EM, Miller TW, Balko JM, et al: A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 71:6773–6784. 2011. View Article : Google Scholar : PubMed/NCBI
21	Suikkari AM, Tiitinen A, Stenman UH, Seppala M and Laatikainen T: Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. Fertil Steril. 55:895–899. 1991.PubMed/NCBI
22	Tas F, Karabulut S, Serilmez M, Ciftci R and Duranyildiz D: Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol. 35:3125–3132. 2014. View Article : Google Scholar : PubMed/NCBI
23	Dursun P, Gultekin M and Esin S: Preoperative serum IGF-1 and IGFBP-3 levels in patients with ovarian carcinoma: preliminary results. Int J Gynecol Cancer. 14:105–106. 2004.
24	Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B and Unluhizarci K: Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol. 24:117–121. 2008. View Article : Google Scholar : PubMed/NCBI
25	El-Roeiy A, Chen X, Roberts VJ, et al: Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1–6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J Clin Endocrinol Metab. 78:1488–1496. 1994. View Article : Google Scholar : PubMed/NCBI
26	Flyvbjerg A, Mogensen O, Mogensen B and Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab. 82:2308–2313. 1997. View Article : Google Scholar : PubMed/NCBI